文章：

Polo样激酶4：连接肿瘤侵袭性与不良预后的多面性标志物及其治疗策略的深入探讨

Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies

原文发布日期：21 September 2023

DOI: 10.3390/cancers15184663

类型: Article

开放获取: 是

英文摘要：

(1) Background: This study investigated whether polo-like kinase 4 (PLK4) is a suitable therapeutic target or biomarker for lung adenocarcinoma (LUAD). (2) Methods: We acquired LUAD data from The Cancer Genome Atlas (TCGA) database through the UCSC Xena data portal. Gene expression, clinical, survival, and mutation data from multiple samples were analyzed. Gene enrichment analysis, unsupervised clustering ofPLK4-related pathways, and differential gene expression analyses were performed. Additionally, correlations,t-tests, survival analyses, and statistical analyses were performed. (3) Results:PLK4expression was higher in LUAD tissues than in normal tissues and was associated with poor prognosis for both overall and progression-free survival in LUAD.PLK4was highly correlated with cell-proliferation-related pathways using Gene Ontology (GO) biological process terms.PLK4expression and pathways that were highly correlated withPLK4expression levels were upregulated in patients with LUAD with theTP53mutation. (4) Conclusions:PLK4expression affects the survival of patients with LUAD and is a potential therapeutic target for LUAD withTP53mutations.

摘要翻译： 

(1) 背景：本研究旨在探讨Polo样激酶4（PLK4）是否可作为肺腺癌（LUAD）的潜在治疗靶点或生物标志物。(2) 方法：通过UCSC Xena数据平台从癌症基因组图谱（TCGA）数据库获取LUAD数据。对多组样本的基因表达、临床特征、生存及突变数据进行分析。研究包括基因富集分析、PLK4相关通路的无监督聚类及差异基因表达分析，并进行了相关性检验、t检验、生存分析和统计分析。(3) 结果：PLK4在LUAD组织中的表达水平显著高于正常组织，且与患者总生存期和无进展生存期的不良预后相关。通过基因本体（GO）生物过程术语分析发现，PLK4与细胞增殖相关通路高度关联。在携带TP53突变的LUAD患者中，PLK4表达及其高度相关的信号通路均呈现上调趋势。(4) 结论：PLK4表达影响LUAD患者的生存状况，可能成为TP53突变型LUAD的潜在治疗靶点。

原文链接：

Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies